Axsome Therapeutics Reports 46% Revenue Growth as Auvelity Accelerates in Alzheimer's Market
The neuroscience-focused biotech posted $218 million in Q2 revenue while launching its lead antidepressant in a new indication and expanding its late-stage pipeline.
Revenue Jumps on Auvelity Strength
Axsome Therapeutics reported second-quarter revenue of $218 million, up 46% year-over-year, as the company's flagship antidepressant Auvelity gained traction in a newly approved indication and the broader commercial portfolio expanded (earnings call, 2026-08-10).
The New York-based neuroscience company, with a market capitalization of approximately $11 billion, posted a net loss of $51.3 million, or $0.99 per share, compared to a $48 million loss in the prior-year quarter. Chief Financial Officer Nick Pizzie noted that the company ended the quarter with $320 million in cash and expects its current balance "is sufficient to fund anticipated operations into cash flow positivity" (earnings call, 2026-08-10).
Auvelity generated $180.3 million in net product sales, representing 51% year-over-year growth and 18% sequential growth. Total prescriptions for the quarter reached approximately 266,000, up 34% year-over-year and 12% sequentially, substantially outpacing the 1-2% growth rates of the broader antidepressant market (earnings call, 2026-08-10).
Alzheimer's Agitation Launch Shows Early Promise
The company launched Auvelity for Alzheimer's disease agitation during the quarter and completed an expansion of its sales force. Chief Commercial Officer Ari Maizel reported that "during the first 8 weeks following the launch in this indication, new-to-brand prescriptions among patients 65 years of age and older increased 126% compared to the same period in the prior quarter" (earnings call, 2026-08-10).
The expanded sales organization activated more than 6,800 new Auvelity prescribers in the quarter, a 21% increase versus the previous quarter, bringing total unique prescribers since launch to approximately 69,000. Market access also improved, with coverage now at approximately 89% of total lives across channels (earnings call, 2026-08-10).
Portfolio Growth Across Three Products
Sunosi, the company's wakefulness-promoting agent, delivered $35.8 million in revenue, up 20% year-over-year, with approximately 61,000 total prescriptions representing 14% annual growth. This outpaced the wakefulness-promoting agent market, which declined 1% year-over-year (earnings call, 2026-08-10).
SYMBRAVO, launched in June 2025 for migraine, posted $2.3 million in net sales with strong underlying demand growth of 30% quarter-over-quarter to approximately 23,500 total prescriptions. However, gross-to-net discounts spiked into "the high 80% range" due to increased patient assistance program utilization, though the company expects this metric to normalize (earnings call, 2026-08-10).
Pipeline Advances Toward Multiple Filings
CEO Herriot Tabuteau highlighted the company's "leading neuroscience pipeline of 6 innovative product candidates" being developed for 10 conditions, positioning Axsome to "potentially file on average one new NDA each year between now and 2030" (earnings call, 2026-08-10).
The FDA accepted the company's NDA submission for AXS-12 for cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. The company is also advancing five Phase III trials of solriamfetol across four new indications: ADHD, binge-eating disorder, major depressive disorder with excessive daytime sleepiness, and shift work disorder. Top-line results from the ENGAGE Phase III trial in binge-eating disorder are anticipated in the fourth quarter of 2026 (earnings call, 2026-08-10).
MarginX data shows recent insider activity included CEO Herriot Tabuteau exercising options and selling 4,660 shares.
This article was generated by MarginX from the earnings call on 2026-08-10. It is not investment advice.